Figure 3

Immunolabelling characteristics of 1A9, 2C3, A11, 6E10 and 4G8 in human brains. Typical AβO immunolabelling is observed in diffuse plaques (arrow) and the perikaryon of pyramidal neurons (arrow head) as dense granules (A and C) or diffuse staining (B) in AD brains (400X): 1A9 (1:50, panel A), 2C3 (1:50, panel B), and A11 (1:250, panel C). In control brains (D), 1A9 disclosed small granular intraneuronal staining in isolated clusters of pyramidal neurons (400X). (E) Diffuse intraneuronal staing is a characteric feature of control brains (A11, 1:250; 400X). (F) 1A9-positive granules were often observed in dendrires (⊔) in AD brains (400X). (G-H) 4G8 (1:100) and 6E10 (1:100) immunoreactivities were also observed in neurons (arrow head) and diffuse plaques (arrow) of AD brains, respectively (400X). (I-K) Determinations of number of intraneuronal AβO immunolabelling in human brains: 1A9 (panel I), 2C3 (panel J), and A11 (panel K). Designations used herein were as follows: Granular, dense granule staining; Diffuse, diffuse staining; None, no staining; NC, normal control; AD, Alzheimer's disease. Experimental results of staining pattern were analyzed by one-way ANOVA, followed by Dannett's test for posthoc analysis: statistical significance compared with NC (*p < 0.01, **p < 0.001).